DYNEX

Designs and manufactures fully-automated ELISA microplate workstations, laboratory instruments and associated consuma... read more

Automated ELISA System Delivers Speed, Precision and Flexibility to Clinical Diagnostic Labs

By LabMedica International staff writers
Posted on 02 Jan 2024

Image: The Agility Integra provides ELISA automation that meets 21 CFR part 11 regulatory compliance (Photo courtesy of DYNEX)

A new fully automated ELISA system featuring the latest enhancements helps achieve powerful lab proficiency while ensuring the security of data to meet all the requirements of 21 CFR Part 11.

DYNEX Technologies (Chantilly, VA, USA) has unveiled the Agility Integra fully automated ELISA system that brings speed, precision, and flexibility to clinical diagnostic laboratories. This high-throughput system comes with upgraded software capabilities for powerful results that comply with FDA Regulation 21 CFR Part 11. Agility Integra’s open system takes ELISA testing to the next level, by allowing multiple immunoassays to run simultaneously. It guarantees data integrity and security with improved audit trails, chain of custody, lab information system connectivity, and secure networking.

With Agility Integra, labs can benefit from high-volume, walk-away processing of multiple assays, faster automation and continuous loading of samples, fewer manual processes and improved workflows, and increased lab efficiency and maximum output, among others. Other advantages include enhanced import and export functionality, upgraded data encryption, and optimized reporting. This latest innovation represents the next step in DYNEX’s flagship automated microplate processor and offers unique value for highly regulated laboratory environments.

DYNEX Vice President of Innovation, Rich Bahlmann, views the Agility Integra system as “a true game changer in the realm of clinical research and drug development, offering superior pipetting accuracy and state-of-the-art data protection.” Mr. Bahlmann is confident that the system “will propel clinical research and drug development initiatives forward, paving the way for groundbreaking advancements within the pharmaceutical and biotechnology field.”

Related Links:
DYNEX Technologies